Efficacy and Safety of Sacubitril/Valsartan in Hypertensive Patients

Efficacy of Sacubitril/Valsartan on out-of-office blood pressure in hypertensive patients - Efficacy of Sacubitril/Valsartan on out-of-office blood pressure in hypertensive patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000060874

Enrollment

Registered

2026-03-09

Start date

2022-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

All patients were switched from renin-angiotensin system inhibitor (angiotensin-converting enzyme inhibitor or angiotensin receptor II blocker) to sacubitril/valsartan. Patients were initially instruc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hypertension 2) Switched from renin-angiotensin inhibitors to sacubitril/valsartan 3) Home blood pressure levels before switching did not achieve the target levels 4) Recording home blood pressure monitoring

Exclusion criteria

Exclusion criteria: 1) Received sacubitril/valsartan less than six months. 2) Non-sinus rhythm 3) Secondary hypertension 4) Myocardial infarction and/or stroke less than 30 days 5) Receiving regular hemodialysis therapy

Design outcomes

Primary

Measure	Time frame
Comparison of home blood pressure after 3 and 6 months	—

Secondary

Measure	Time frame
1. Change in office blood pressure 2. Change in liner function and electrolytes 3. Change in NT-proBNP	—

Countries

Japan

Contacts

Public ContactYoshio Iwashima

Osaka University Graduate School of Medicine, Department of Geriatric and General Medicine

iwashima@geriat.med.osaka-u.ac.jp0668793852

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026